Signant Health Enters Definitive Agreement to Acquire Ametris

Signant Health has announced a definitive agreement to acquire Ametris, a global provider of digital health solutions, for an undisclosed amount. The transaction, revealed on April 16, 2026, is subject to customary regulatory processes and approvals, with further details regarding the acquisition and the combined offerings expected to be disclosed upon completion.

Signant Health, headquartered in Philadelphia, is recognized as a leader in evidence generation, focusing on leveraging advanced software and deep therapeutic expertise to enhance clinical studies. The company has built a robust portfolio of solutions that support various trial models, including traditional, virtual, and hybrid formats. With over 25 years of experience, Signant Health serves more than 600 sponsors and contract research organizations (CROs), including all of the top 20 pharmaceutical companies. This acquisition aligns with Signant's strategic goal of expanding its capabilities in the digital health space, enhancing its offerings in electronic clinical outcome assessments (eCOA), electronic data capture (EDC), and other critical areas.

Ametris, formerly known as ActiGraph, specializes in providing digital health solutions that enable the collection and analysis of health data. The company's innovative technologies are designed to improve patient engagement and streamline data collection processes in clinical trials. By integrating Ametris's capabilities, Signant Health aims to strengthen its position in the digital health sector, which has seen significant growth due to the increasing demand for remote patient monitoring and data-driven healthcare solutions.

The acquisition comes at a time when the healthcare industry is rapidly evolving, with digital health solutions becoming increasingly vital in clinical research. The COVID-19 pandemic has accelerated the adoption of remote monitoring technologies, and companies are now seeking to enhance their digital offerings to meet the changing needs of patients and sponsors alike. By acquiring Ametris, Signant Health is poised to capitalize on these trends, further solidifying its role as a comprehensive provider of evidence generation solutions.

As the market for digital health continues to expand, this acquisition highlights the ongoing consolidation within the sector. Companies are increasingly looking to enhance their technological capabilities and service offerings through strategic partnerships and acquisitions. The integration of Ametris into Signant Health's portfolio is expected to create synergies that will enhance operational efficiencies and drive innovation in clinical trial methodologies, ultimately benefiting stakeholders across the healthcare landscape.